1. Home
  2. ANAB vs DAO Comparison

ANAB vs DAO Comparison

Compare ANAB & DAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$47.66

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Youdao Inc. each representing one

DAO

Youdao Inc. each representing one

HOLD

Current Price

$11.00

Market Cap

1.4B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
DAO
Founded
2005
2006
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
ANAB
DAO
Price
$47.66
$11.00
Analyst Decision
Buy
Analyst Count
12
0
Target Price
$60.18
N/A
AVG Volume (30 Days)
499.2K
124.6K
Earning Date
02-26-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
155.59
EPS
N/A
0.17
Revenue
$169,467,000.00
$798,421,874.00
Revenue This Year
$135.51
$5.12
Revenue Next Year
N/A
$12.82
P/E Ratio
N/A
$67.75
Revenue Growth
196.42
N/A
52 Week Low
$12.21
$6.30
52 Week High
$52.47
$12.96

Technical Indicators

Market Signals
Indicator
ANAB
DAO
Relative Strength Index (RSI) 53.20 48.47
Support Level $46.06 $10.58
Resistance Level $50.00 $11.61
Average True Range (ATR) 3.02 0.80
MACD -0.05 -0.18
Stochastic Oscillator 64.38 10.32

Price Performance

Historical Comparison
ANAB
DAO

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About DAO Youdao Inc. each representing one

Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.

Share on Social Networks: